Benjamin P. Levy, MD, discusses the role of biomarkers in the treatment landscape for patients with lung cancer.
Benjamin P. Levy, MD, an associate professor at Johns Hopkins School of Medicine and clinical director for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the role of biomarkers in the treatment landscape for patients with lung cancer.
More recently, physicians have gotten a firmer understanding of the genomic underpinnings of tumors, says Levy. This began with EGFR mutations and moved toward the ALK mutations. Most recently, Levy says we have learned there are other actionable mutations in lung cancer besides EGFR and ALK.
Other driver mutations in lung cancer induce RET rearrangements, NTRK fusions, and MET exon 14 skipping mutations. These are important for identifying appropriate genotype-directed therapies for patients with lung cancer.
In nonsmall cell lung cancer in particular, this is not a one-size-fits-all model, Levy notes. Patients should be categorized into distinct genomic subsets in which particular targeted therapies are known to outperform chemotherapy, he concludes.
<< View more resources and information regarding biomarker-driven lung cancers
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More